1 1

Tesamorelin (2mg)

Tesamorelin (2mg)

$35.00 USD
$35.00 USD
Sale Sold out
Shipping calculated at checkout.

Overview:
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH 1–44) designed to stimulate endogenous growth hormone (GH) secretion from the anterior pituitary. Originally approved for HIV-associated lipodystrophy, Tesamorelin has gained attention for its potent ability to reduce visceral adipose tissue (VAT) and improve metabolic parameters without significantly altering subcutaneous fat.

Tesamorelin is currently being explored for broader applications including nonalcoholic steatohepatitis (NASH), metabolic syndrome, and age-related fat redistribution, marking it as a key player in GH-axis targeted therapies.

View full details

COA

Third-Party Testing

PubChem Information

https://pubchem.ncbi.nlm.nih.gov/compound/16137828

What is Tesamorelin?

  • Mechanism of Action:

    Tesamorelin mimics endogenous GHRH and binds to GHRH receptors in the pituitary, leading to pulsatile GH release:

    • Pituitary Activation: Enhances physiological GH secretion, avoiding pituitary suppression.
    • IGF-1 Production: Indirectly stimulates the liver to produce IGF-1, which mediates many anabolic and lipolytic effects of GH.
    • Visceral Fat Reduction: GH/IGF-1 signaling promotes lipolysis, particularly in visceral adipose depots, while preserving lean mass.
    • Metabolic Effects: Enhances lipid oxidation, improves glucose metabolism, and may reduce hepatic steatosis.

    This mechanism allows Tesamorelin to act safely and specifically, without causing supraphysiologic GH elevations.

  • Preclinical and Clinical Studies:

    HIV-Associated Lipodystrophy (FDA-Approved Indication):

    • Reduced visceral adipose tissue (VAT) by ~15–18% after 26 weeks.
    • Improved triglycerides, total cholesterol, and body image perception.
    • No significant change in limb or subcutaneous fat.

    Nonalcoholic Fatty Liver Disease (NAFLD/NASH):

    • Reduced hepatic fat fraction and NAFLD Activity Score (NAS) in multiple trials.
    • Improvements in liver inflammation, ballooning, and steatosis.
    • Potential future role in treating metabolic-associated steatohepatitis (MASH).

    Metabolic and Endocrine Effects:

    • Increased IGF-1 levels without exogenous GH.
    • No suppression of cortisol or gonadotropins.
    • Modestly improves insulin sensitivity over time.

    Aging and Preventive Health (Emerging Use):

    • Explored for visceral fat reduction in aging adults.
    • Potential in sarcopenia, vascular health, and cognitive decline under investigation.

  • Intended Use:

    • The information provided on this site is intended exclusively for educational and research purposes and should not be interpreted as medical guidance.
    • Research compounds, including Tesamorelin, are designed solely for laboratory investigation by qualified professionals and are not intended for human use or consumption.
    • The statements presented here have not been evaluated by the U.S. Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease.